Very nice!
$INVO Bioscience(INVO.US$ Q1 2024 Financial Highlights (all metrics compared to Q1 2023 unless otherwise noted)
● Revenue was $1,576,286, an increase of 353% compared to $348,025.
● Clinic revenue increased 417% to $1,537,199, compared to $297,381. All reported clinic revenue is derived from the Company’s INVO Center in Atlanta, Georgia, and its IVF clinic in Madison, Wisconsin, which are consolidated in the Company’s financial statements.
● Revenue from all clinics, inclusive of both those accounted for as consolidated and under the equity method, was $1,869,513, an increase of 189% compared to $646,707.
● Total operating expenses were $2.5 million, a $0.1 million decrease compared to $2.6 million. Included in the Q1 2024 operating expenses were approximately $80,000 pertaining to the definitive merger agreement with NAYA Biosciences, Inc. (“NAYA”) to acquire NAYA in an all-stock transaction.
● Reported Net loss was $(1.6) million compared to $(2.6) million.
● Adjusted EBITDA (see table included) was $(0.5) million, including the transaction costs related to the potential merger, compared to $(1.7) million in the prior year.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : Wow the repeat best performer!
TrytosaveabitOP Jaguar8: Yup! Im taking it for another ride! Hopefully it will turn out like the last a few weeks back! Hehehe
Jaguar8 TrytosaveabitOP: This was a memorable ER trade for me